CHIH-HAO CHENLiu C.-H.Chi N.-F.Sung P.-S.Hsieh C.-Y.Lee M.SUNG-CHUN TANGJIANN-SHING JENGTaiwan Stroke Society Investigators2020-11-032020-11-0320202287-6391https://www.scopus.com/inward/record.uri?eid=2-s2.0-85092167257&doi=10.5853%2fjos.2020.02292&partnerID=40&md5=ec84fbf11860b8f5b32e216238a6aa35https://scholars.lib.ntu.edu.tw/handle/123456789/519289[SDGs]SDG3anticoagulant agent; antilipemic agent; tissue plasminogen activator; atrial fibrillation; brain hemorrhage; cerebrovascular accident; computer assisted tomography; coronavirus disease 2019; government; health care quality; hospital admission; human; Letter; major clinical study; National Institutes of Health Stroke Scale; practice guideline; retrospective study; stroke unit; Taiwan; time to treatment; total quality managementletter10.5853/jos.2020.022922-s2.0-85092167257